NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- SHANGHAI A&I CO., LTD.: HKEX IPO Application Lapses, a Leading Provider of Integrated Intelligent Manufacturing System Solutions in China
- Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) Rises 1.32% in Afternoon Trade, Turnover at HKD 1.359 Billion
- Autonomous Driving Concept Stocks Watch | XPENG-W(09868.HK) Trades Weakly and Volatile in Afternoon Session; TuringViT Efficient Vision Encoder Officially Launched
- Ping An of China CSI HK Dividend ETF(03070.HK) Rises 0.35% Intraday, Assets Under Management Reach HK$1.449 Billion
- CSOP FTSE East-West Equity Select ETF(03441.HK) Rises 0.64% Intraday With AUM of HK$1.548 Billion
